

GLAXOSMITHKLINE PLC  
Form 6-K  
October 18, 2016

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION  
Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of  
the Securities Exchange Act of 1934

For period ending 18 October 2016

GlaxoSmithKline plc  
(Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS  
(Address of principal executive offices)

Indicate by check mark whether the registrant files or  
will file annual reports under cover Form 20-F or Form 40-F

Form 20-F  Form 40-F

--

Indicate by check mark whether the registrant by furnishing the  
information contained in this Form is also thereby furnishing the  
information to the Commission pursuant to Rule 12g3-2(b) under the  
Securities Exchange Act of 1934.

Yes No

GlaxoSmithKline plc (the 'Company')

Transaction notification

1. Details of PDMR/person closely associated with them ('PCA')

- a) Name Sir Andrew Witty
- b) Position/status Chief Executive Officer
- c) Initial notification/  
amendment Initial notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

- a) Name GlaxoSmithKline plc
- b) LEI 5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

- a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')  
ISIN: GB0009252882

- b) Nature of the transaction Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 13 October 2016 on Ordinary Shares held in the Company's 2009 Performance Share Plan.

	Price(s)	Volume(s)
	£17.00	3.852
	£17.00	210.425
c) Price(s) and volume(s)	£17.00	562.209
	£17.00	1288.273
	£17.00	3864.847

£17.00 5283.681

£17.00 5722.843

Aggregated information

- d) Aggregated volume Price 16,936.13  
£17.00
- e) Date of the transaction 2016-10-13
- f) Place of the transaction n/a

1. Details of PDMR/person closely associated with them ('PCA')

- a) Name Ms E Walmsley
- b) Position/status CEO Designate
- c) Initial notification/  
amendment Initial notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

- a) Name GlaxoSmithKline plc
- b) LEI 5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

- a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')  
ISIN: GB0009252882
- b) Nature of the transaction Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 13 October 2016 on Ordinary Shares held

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

in the Company's 2009  
Performance Share Plan.

	Price(s)	Volume(s)
	£17.00	711.971
c) Price(s) and volume(s)	£17.00	1339.653
	£17.00	1373.598
	£17.00	2344.931

d) Aggregated information  
Aggregated volume Price

5,770.153  
£17.00

e) Date of the transaction 2016-10-13

f) Place of the transaction n/a

1. Details of PDMR/person closely associated with them ('PCA')

a) Name Mr S Dingemans  
b) Position/status Chief Financial Officer  
c) Initial notification/  
amendment Initial notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a) Name GlaxoSmithKline plc  
b) LEI 5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')  
ISIN: GB0009252882

b) Nature of the transaction

Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 13 October 2016 on Ordinary Shares held in the Company's 2009 Performance Share Plan.

	Price(s)	Volume(s)
c) Price(s) and volume(s)	£17.00	2267.631
	£17.00	2325.081
	£17.00	2518.157

d) Aggregated information

Aggregated volume Price

7,110.869  
£17.00

e) Date of the transaction

2016-10-13

f) Place of the transaction

n/a

1. Details of PDMR/person closely associated with them ('PCA')

a) Name

Mr R G Connor

b) Position/status

President, Global Manufacturing & Supply

c) Initial notification/ amendment

Initial notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a) Name

GlaxoSmithKline plc

b) LEI 5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')  
ISIN: GB0009252882

b) Nature of the transaction Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 13 October 2016 on Ordinary Shares held in the Company's 2009 Performance Share Plan.

	Price(s)	Volume(s)
c) Price(s) and volume(s)	£17.00	1042.651
	£17.00	1069.072
	£17.00	1369.301

d) Aggregated information  
Aggregated volume Price 3,481.024  
£17.00

e) Date of the transaction 2016-10-13

f) Place of the transaction n/a

1. Details of PDMR/person closely associated with them ('PCA')

a) Name Mr L Debruyne

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

- b) Position/status President, Global Vaccines  
GSK
- c) Initial notification/  
amendment Initial notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
- a) Name GlaxoSmithKline plc
- b) LEI 5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

- a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')  
ISIN: GB0009252882

- b) Nature of the transaction Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 13 October 2016 on Ordinary Shares held in the Company's 2009 Performance Share Plan.

- |                           | Price(s) | Volume(s) |
|---------------------------|----------|-----------|
| c) Price(s) and volume(s) | £17.00   | 273.464   |
|                           | £17.00   | 298.195   |
|                           | £17.00   | 344.671   |

- d) Aggregated information  
Aggregated volume Price 916.330  
£17.00

- e) Date of the transaction 2016-10-13
- f) Place of the transaction n/a

1. Details of PDMR/person closely associated with them ('PCA')

- |                                       |                                 |
|---------------------------------------|---------------------------------|
| a) Name                               | Mr N Hirons                     |
| b) Position/status                    | SVP, Global Ethics & Compliance |
| c) Initial notification/<br>amendment | Initial notification            |

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

- |         |                      |
|---------|----------------------|
| a) Name | GlaxoSmithKline plc  |
| b) LEI  | 5493000HZTVUYLO1D793 |

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

- |  |   |           |
|--|---|-----------|
| a) Description of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares')<br>ISIN: GB0009252882  |           |
| b) Nature of the transaction               | Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 13 October 2016 on Ordinary Shares held in the Company's 2009 Performance Share Plan. |           |
| c) Price(s) and volume(s)                  | Price(s)  | Volume(s) |
|  | £17.00  | 518.340   |
|  | £17.00  | 564.838   |
| d) Aggregated information                  |   |           |

Aggregated volume Price



1,083.178  
£17.00

- e) Date of the transaction 2016-10-13  
f) Place of the transaction n/a

1. Details of PDMR/person closely associated with them ('PCA')

- a) Name Mr S A Hussain  
b) Position/status President, Global Pharmaceuticals  
c) Initial notification/amendment Initial notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

- a) Name GlaxoSmithKline plc  
b) LEI 5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

- a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')  
ISIN: GB0009252882
- b) Nature of the transaction Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 13 October 2016 on Ordinary Shares held in the Company's 2009 Performance Share Plan.
- c) Price(s) and volume(s)
- | Price(s) | Volume(s) |
|----------|-----------|
| £17.00   | 2105.069  |

£17.00 2429.724

£17.00 2738.614

Aggregated information

d) Aggregated volume Price 7,273.407  
£17.00

e) Date of the transaction 2016-10-13

f) Place of the transaction n/a

1. Details of PDMR/person closely associated with them ('PCA')

a) Name Mr D S Redfern  
b) Position/status Chief Strategy Officer  
c) Initial notification/  
amendment Initial notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a) Name GlaxoSmithKline plc  
b) LEI 5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')  
ISIN: GB0009252882  
b) Nature of the transaction Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 13 October 2016 on Ordinary Shares held

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

in the Company's 2009  
Performance Share Plan.

	Price(s)	Volume(s)
c) Price(s) and volume(s)	£17.00	748.492
	£17.00	850.396
	£17.00	992.738

d) Aggregated information  
Aggregated volume Price

2,591.626  
£17.00

e) Date of the transaction 2016-10-13

f) Place of the transaction n/a

1. Details of PDMR/person closely associated with them ('PCA')

a) Name Ms C Thomas

b) Position/status SVP, HR

c) Initial notification/  
amendment Initial notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a) Name GlaxoSmithKline plc

b) LEI 5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')  
ISIN: GB0009252882

b) Nature of the transaction

Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 13 October 2016 on Ordinary Shares held in the Company's 2009 Performance Share Plan.

	Price(s)	Volume(s)
c) Price(s) and volume(s)	£17.00	1067.932
	£17.00	1133.866
	£17.00	1249.482

d) Aggregated information  
Aggregated volume Price

3,451.28  
£17.00

e) Date of the transaction 2016-10-13

f) Place of the transaction n/a

1. Details of PDMR/person closely associated with them ('PCA')

- |                                    |  |
|------------------------------------|--|
| a) Name                            | Mr P C Thomson                           |
| b) Position/status                 | SVP, Communications & Government Affairs |
| c) Initial notification/ amendment | Initial notification                     |

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

- |         |                      |
|---------|----------------------|
| a) Name | GlaxoSmithKline plc  |
| b) LEI  | 5493000HZTVUYLO1D793 |

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a) Description of the financial instrument	Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882	
b) Nature of the transaction	Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 13 October 2016 on Ordinary Shares held in the Company's 2009 Performance Share Plan.	
c) Price(s) and volume(s)	Price(s)	Volume(s)
	£17.00	509.321
	£17.00	656.026
	£17.00	718.885
d) Aggregated information		
Aggregated volume	1,884.232	
Price	£17.00	
e) Date of the transaction	2016-10-13	
f) Place of the transaction	n/a	

1. Details of PDMR/person closely associated with them ('PCA')

a) Name	Dr P J T Vallance
b) Position/status	President, Pharmaceuticals R&D
c) Initial notification/ amendment	Initial notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

- a) Name GlaxoSmithKline plc
- b) LEI 5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

- a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')  
ISIN: GB0009252882
- b) Nature of the transaction Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 13 October 2016 on Ordinary Shares held in the Company's 2009 Performance Share Plan.

	Price(s)	Volume(s)
c) Price(s) and volume(s)	£17.00	2300.167
	£17.00	2358.444
	£17.00	2909.770

- d) Aggregated information  
Aggregated volume Price 7,568.381  
£17.00

e) Date of the transaction 2016-10-13

f) Place of the transaction n/a

1. Details of PDMR/person closely associated with them ('PCA')

- a) Name Mrs V A Whyte

- b) Position/status Company Secretary
- c) Initial notification/  
amendment Initial notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
- a) Name GlaxoSmithKline plc
- b) LEI 5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

- a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')  
ISIN: GB0009252882
- b) Nature of the transaction Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 13 October 2016 on Ordinary Shares held in the Company's 2009 Performance Share Plan.
- |                           | Price(s) | Volume(s) |
|---------------------------|----------|-----------|
| c) Price(s) and volume(s) | £17.00   | 137.240   |
|                           | £17.00   | 145.217   |
|                           | £17.00   | 153.140   |
- d) Aggregated information  
Aggregated volume Price 435.597  
£17.00
- e) Date of the transaction 2016-10-13
- f) Place of the transaction n/a

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GlaxoSmithKline plc  
(Registrant)  
Date: October 18, 2016

By: VICTORIA WHYTE

-----

Victoria Whyte  
Authorised Signatory for and on  
behalf of GlaxoSmithKline plc